News Releases

The latest news about Samsung Bioepis

Samsung Bioepis Wins Two iF Design Awards

• Second international design award win followed by Red Dot Design Award in 2020
• ‘Passion for Health’ design recognized for its patient-centricity and design originality


INCHEON, KOREA – April 22, 2021 – Samsung Bioepis Co., Ltd. today announced that it has received two awards at the world-renowned International Forum (iF) Design Award 2021 for its brand identity. Samsung Bioepis won two categories: Packaging - Medicine/Pharmaceutics and Communication - Corporate Identity/Branding. The winning design, titled ‘Passion for Health: Pure Joy in Life,’ was inspired by tranquility of nature and organic forms in life. 

In 2020, Samsung Bioepis also won Red Dot Awards for the same brand identity in two categories: Brand Design & Identity and Packaging Design.

“We are honored to have our brand design recognized by two distinguished international design awards. Taking medication can be a constant reminder of the medical condition, and we wanted to remind patients of ‘pure joy’ in life when they look at our product packaging and design,” said Jaywoo Kim, Senior Vice President, Manufacturing Division Leader, at Samsung Bioepis. “As a global biopharmaceutical company recognized for its excellence in quality, from cell line development to packaging design, we remain committed to enhancing the lives of patients through our innovative use of science and technology to develop biosimilar medicines,” he added.

Organized by iF International Forum Design GmbH, the iF Design Award is recognized as one of the world's most celebrated design competitions. The iF Design Award 2021 was presented in nine disciplines & categories – Product Design, Communication Design, Architecture, Interior Architecture, Professional Concept, Service Design, User Experience (UX), and User Interface (UI).

# # #

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology. For more information, please visit: and follow us on social media– Twitter, LinkedIn.


Anna Kim: